Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

826.46
+2.400.29%
Volume:1.40M
Turnover:1.15B
Market Cap:783.62B
PE:70.58
High:833.96
Open:820.67
Low:813.26
Close:824.06
Loading ...

Morning Brew: Honeywell's Split and Roblox's Strong Q4 Performance

GuruFocus
·
06 Feb

Here’s Why Eli Lilly (LLY) Traded Down in Q4

Insider Monkey
·
06 Feb

Traders Digest Earnings Deluge as US Equity Futures Tread Water Pre-Bell

MT Newswires Live
·
06 Feb

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Dow Jones
·
06 Feb

5 Things to Know Before the Stock Market Opens

Investopedia
·
06 Feb

Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs

GuruFocus.com
·
06 Feb

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Blockhead
·
06 Feb

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Benzinga
·
06 Feb

Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates

Zacks
·
06 Feb

Lilly says Mounjaro and Zepbound contributed to big revenue boost

Dow Jones
·
06 Feb

BRIEF-Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

Reuters
·
06 Feb

Eli Lilly Reports Q4 2024 Earnings: EPS at $4.88, Revenue Hits $13.53 Billion, Missing Analyst Estimates

GuruFocus
·
06 Feb

Palatin Technologies Inc - Topline Data Results Expected Later This Quarter

THOMSON REUTERS
·
06 Feb

Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

THOMSON REUTERS
·
06 Feb

US STOCKS-Futures subdued as investors assess big corporate results

Reuters
·
06 Feb

Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss

Blockhead
·
06 Feb